Johnson & Johnson $JNJ Shares Sold by Firethorn Wealth Partners LLC

Firethorn Wealth Partners LLC cut its position in shares of Johnson & Johnson (NYSE:JNJ) by 16.5% during the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 4,496 shares of the company’s stock after selling 889 shares during the quarter. Firethorn Wealth Partners LLC’s holdings in Johnson & Johnson were worth $687,000 as of its most recent filing with the SEC.

Several other large investors have also bought and sold shares of the company. Highline Wealth Partners LLC boosted its position in shares of Johnson & Johnson by 51.8% during the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock valued at $42,000 after purchasing an additional 86 shares in the last quarter. Stone House Investment Management LLC acquired a new stake in Johnson & Johnson during the first quarter valued at approximately $47,000. 1248 Management LLC bought a new stake in Johnson & Johnson during the first quarter worth approximately $48,000. von Borstel & Associates Inc. acquired a new stake in shares of Johnson & Johnson during the 1st quarter valued at $49,000. Finally, Harvest Fund Management Co. Ltd bought a new stake in shares of Johnson & Johnson during the 1st quarter worth $52,000. Institutional investors own 69.55% of the company’s stock.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the firm’s stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the transaction, the executive vice president owned 178,013 shares in the company, valued at approximately $31,652,491.53. This trade represents a 24.08% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Down 0.2%

JNJ stock opened at $188.23 on Tuesday. The company has a 50 day moving average of $176.62 and a two-hundred day moving average of $163.00. The company has a market cap of $453.32 billion, a price-to-earnings ratio of 20.13, a PEG ratio of 2.40 and a beta of 0.40. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $189.92. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, topping analysts’ consensus estimates of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The business had revenue of $23.74 billion for the quarter, compared to the consensus estimate of $22.85 billion. During the same period in the prior year, the business posted $2.82 earnings per share. Johnson & Johnson’s revenue for the quarter was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, equities analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were given a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 2.8%. The ex-dividend date of this dividend was Tuesday, August 26th. Johnson & Johnson’s payout ratio is currently 55.61%.

Analysts Set New Price Targets

JNJ has been the subject of a number of recent analyst reports. Citigroup increased their price target on Johnson & Johnson from $185.00 to $200.00 and gave the company a “buy” rating in a research report on Thursday, August 21st. Wall Street Zen upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a report on Saturday, September 13th. Piper Sandler restated an “overweight” rating on shares of Johnson & Johnson in a report on Thursday, July 17th. Guggenheim upgraded shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $167.00 to $206.00 in a research report on Tuesday, September 23rd. Finally, Royal Bank Of Canada increased their target price on Johnson & Johnson from $181.00 to $185.00 and gave the company an “outperform” rating in a report on Thursday, July 17th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat.com, Johnson & Johnson currently has an average rating of “Moderate Buy” and a consensus target price of $189.12.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.